Dupilumab normalizes the eosinophilic esophagitis disease transcriptome.

What was studied

This study looked at dupilumab in people with eosinophilic esophagitis, or EoE. EoE causes type 2 inflammation in the esophagus. Dupilumab is a drug that blocks IL-4 and IL-13 signals. The team took tissue samples from the esophagus before and after treatment. Samples came from kids, teens and adults in 3 trials. In each trial, some people got dupilumab and others got a dummy drug. The team looked at which genes were turned on or off in the tissue.

What they found

In EoE, many genes in the esophagus act in an unusual way. After dupilumab, these gene patterns moved a lot back toward normal. This was true for genes linked to eosinophils and mast cells. It was also true for genes tied to scarring and the tissue barrier. Other cell tasks and pathways changed too. In all, 41 body processes that were off in EoE went back to normal. Some of these likely do not depend on eosinophils. The changes were alike in kids, teens and adults. They lasted through week 52.

What it means for patients

The authors say IL-4 and IL-13 drive the key tissue changes in EoE. These are the gene differences seen versus people without the disease. Blocking these signals with dupilumab brought the genes back toward normal. The authors say this fits with how dupilumab helps people with EoE.

Why it is not certain yet

The abstract does not say how many people gave samples. It does not give exact results for the dummy drug groups. This study looked at genes, not at symptoms. Results in the abstract go to week 52, so longer effects are unknown. The abstract also does not report side effects.

Source

Dupilumab normalizes the eosinophilic esophagitis disease transcriptome.

We restate facts from the source record in our own words. The original wording belongs to its publisher.